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Vasoactive properties of plasma samples taken from the
coronary sinus, a systemic artery and the superior vena
cava of 13 patients with angiographically proven coro-
nary artery disease and from 5 patients with normal
coronary arteriograms were assayed in vitro by mea-
surement of the changes in tension of rings of isolated
canine coronary arteries. Addition of 1 ml samples of
platelet-rich plasma from the coronary sinus of patients
with coronary artery disease into a 20 ml organ bath
induced an initial relaxation followed by sustained con-
striction in bioassay coronary artery rings with endo-
thelium and only vasoconstriction in rings without en-
dothelium.
The vasoconstrictor activity of the coronary sinus
plasma showed positivecorrelation with the severity and
extent of coronary artery narrowing. Systemic arterial
A relation exists between atheromatous coronary artery dis-
ease and the frequent occurrence of vasospastic episodes in
epicardial coronary arteries (1-4), but the exact mechanism
involved remains obscure. It is postulated that such episodes
are due to either hypersensitivity of vascular smooth muscle
to normally occurring stimuli or the activation of pathologic
vasoconstrictor mechanisms (5-8). As a means of distin-
guishing between these two equally possible mechanisms,
a study was initiated to investigate whether the coronary
sinus blood of patients with organic coronary artery stenosis
exhibits vasoconstrictor activity in an in vitro bioassay sys-
tem. For comparison, the vasoactive properties of plasma
taken simultaneously from a systemic artery and vein in
patients with coronary artery disease or of the coronary sinus
plasma from subjects with no coronary artery disease were
determined as well. Plasma samples were taken during rest
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and venous plasma samples from patients with coronary
artery disease and the coronary sinus plasma from pa-
tients with no coronary artery disease evoked only en-
dothelium-dependent relaxations. These vasoactive
properties of the various plasma samples were similar
whether the samples were taken during rest or during
supine bicycle exercise. The serotoninergic receptor an-
tagonist methiothepin prevented the vasoconstriction in-
duced by the coronary sinus plasma samples.
These data demonstrate that the coronary sinus blood
of patients with atheromatous coronary artery disease
exhibits vasoconstrictor activity that may be associated
with 5-hydroxytryptamine (serotonin), presumably reo
leased from platelets.
(J Am Coil CardioI1987;9:1243-9)
and supine bicycle exercise to analyze the possible relation
between myocardial ischemia and vasoactive properties of
the plasma.
Methods
Study patients. Eighteen patients were studied; 17 (14
men and 3 women) had coronary arteriography for the eval-
uation of chest pain, and 1 man underwent endomyocardial
biopsy. The age range was 30 to 66 years. The clinical
diagnosis before coronary angiography was definite angina
pectoris in 11, probable angina in 4 and noncardiac chest
pain in 3. Two patients had a history of inferior myocardial
infarction. All were clinically stable and had sinus rhythm;
none had congestive heart failure.
Coronary artery disease was defined on the basis of the
luminal diameter narrowing of any individual coronary ar-
tery branch as follows: significant :::>:50% narrowing (n =
9); mild, :::>:20% to 50% (n = 4). Five patients had no
apparent arteriographic signs of coronary artery disease. The
extent of disease was defined as the sum of individual coro-
nary arteries with a :::>:50% luminal diameter narrowing (left
main, right, left anterior descending, diagonal, septal, left
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circumflex, obtuse marginal). With this scheme, the distri-
bution of extent of significant disease in nine patients was
as follows: two each had one vessel, two vessel, three vessel
and four vessel disease and one had five vessel disease. The
distribution of angina and coronary artery disease reflects
selection of patients with documented normal coronary ar-
teriograms for the purposes of this study.
In 13 of the 18 patients, plasma samples were taken
immediately before the coronary arteriographic procedure,
after at least 12 hours of fasting and premedication with
diazepam. In the remaining five patients, sampling was per-
formed 9 to 28 days later. Of the 13 patients with docu-
mented coronary artery disease, 9 received no antianginal
treatment within 12 to 18 hours of the study and 4 received
a beta-adrenergic receptor blocker or a calcium antagonist
(or both) within 7 hours. Of the five patients with normal
coronary arteriograms, one received nifedipine 11f2 hours
before the study and the others either were not receiving
medication or had not received any for 24 to 48 hours.
Cardiac catheterization technique and test procedure.
A no. 7 Lehman catheter was placed in the coronary sinus
percutaneously from the right internal jugular vein. In five
patients, a second identical catheter was placed in the su-
perior vena cava to allow simultaneous sampling from the
superior vena cava and coronary sinus. In 12 patients, iden-
tical sampling was carried out during supine leg exercise,
starting at 300 kilopond-meters (kp-m), with a bicycle er-
gometer for 4 to 5 minutes. Additional levels of exercise at
600 and 900 kp-m were performed, depending on the pa-
tient's response. During exercise. five of eight patients with
coronary artery disease had typical chest pain associated
with ECG signs of myocardial ischemia. Arterial blood was
sampled from the brachial artery. All catheters were flushed
with heparinized saline solution.
Blood samples and the in vitro bioassay technique.
After the first 2.5 to 3.0 ml of blood (dead space of the
catheters) was discarded, a 5 to 20 ml sample was slowly
withdrawn into a plastic syringe and was then immediately
transferred into chilled assay tubes containing heparin. The
tubes were quickly immersed in crushed ice. Within the
following 2 hours, the blood samples were centrifuged at
room temperature either at 750 g for 20 minutes to obtain
platelet-rich plasma or at 3,000 g for 30 minutes to obtain
platelet-poor plasma (9). The vasoactive properties of the
plasma were then immediately assayed in vitro. At the time
of assay, the investigator performing the in vitro studies
(G.M.R.) did not know the identity of any patient, the
symptoms of the patient or the results of angiography.
The hearts of anesthetized (sodium pentobarbital, 30
mglkg) mongrel dogs (15 to 25 kg) were removed. The left
circumflex coronary artery was dissected free and placed in
cold physiologic saline solution and cleaned of adherent
loose connective and adipose tissue. Coronary artery rings,
4 mm in length, were prepared and mounted by a method
developed and routinely used in our laboratory (10). The
rings were mounted for isometric tension recordings in in-
dividual organ chambers filled with 20 ml of modified Krebs-
Ringer-bicarbonate solution (composition in mmol/liter: so-
dium chloride, 118.3; potassium chloride, 4.7; magnesium
sulfate, 1.2; potassium biphosphate, 1.2; calcium chloride,
2.5; sodium bicarbonate, 25.0; calcium ethylenediamine-
tetraacetic acid, 0.026; glucose, 11.1) continuously bubbled
with a gas mixture of 95% oxygen and 5% carbon dioxide
(pn, 7.4) and left at 37°C. The rings were connected to
force transducers (Gould UTC2) for measurement of iso-
metric tension. They were stretched to obtain approximately
109 of tension, stimulated with 20 mM of potassium chlo-
ride three times and then equilibrated for at least 30 minutes
before experimentation. In some rings, the endothelium was
removed mechanically by gentle rubbing of the intimal sur-
face before mounting in the organ chamber. The presence
and absence of functional endothelium were tested by the
presence and absence, respectively, of relaxation to ace-
tylcholine (II). Rings with or without endothelium from
the same coronary artery were studied in parallel. The va-
soactive properties of I ml plasma samples (in a 20 ml bath)
were studied in nonstimulated rings, which exhibited spon-
taneous (basal) active myogenic tone. Rings with and with-
out endothelium showed similar active basal tension (1.5
± 0.5 and 1.6 ± 0.4 g, respectively), as measured by
relaxation to acetylcholine (10 6 M) or sodium nitroprusside
(10- 5 M).
Drugs. The following drugs were used: acetylcholine
hydrochloride (Sigma), apyrase (Sigma), indomethacin
(Sigma), mepyramine (Sigma), methiothepin, nitroprusside
sodium (Sigma), nordihydroguaiaretic acid (Sigma), phen-
tolamine mesylate (Ciba-Geigy) and DL-propranolol (Sigma).
Stock solutions of the drugs were prepared daily in distilled
water and kept on ice. Indomethacin was dissolved in 1.5
x 10- 5 M sodium carbonate solution by sonication. Drugs
were added to the bath solution in a volume of less than
150 JLI, and the concentration of the drugs was always
indicated as final molar concentration in the organ bath.
Calculations and statistical analysis. Results are given
as mean ± SEM. Correlation between vasoconstrictor ac-
tivity of the plasma and the number of narrowed vessels
was calculated by linear regression analysis. Statistical anal-
ysis was performed by Student's t test for paired and un-
paired observations. When probability (p) was < 0.05, the
differences were reported as statistically significant.
Results
Vasoactive Properties of the PLasma SampLes
Patients with coronary artery disease (Fig. 1 to 3).
Isometric tension recordings of a typical experiment are
shown in Figure I. At a dilution of I :20, platelet-rich plasma
taken from the brachial artery of the 13 patients with coro-
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Figure 1. Representative original recording of bioas-
say of vasoactive properties of platelet-rich plasma
samples taken frombrachial artery, coronary sinusand
superior vena cava of a patient with angiographically
verified coronary arterydisease. Plasma sample (I ml)
was added to a 20 ml organ bath in which isolated
rings of canine coronary artery with (upper tracing)
or without (lower tracing) endothelium were mounted
for isometric tension recording. Presence and absence
of functional endothelium were testedby presence and
absence, respectively, of relaxations inresponseto ace-
tylcholine (ACh, 10- 6 M) in ringscontracted with po-
tassium chloride (KCI, 20 mM). Plasma samples in-
duced biphasic changes in tension of quiescent coronary
artery ringswithendothelium. Initial relaxation (phase
I) was followed by sustained contraction (phase 2),
which exceeded initial tension level significantly only
with plasma samples taken from the coronary sinus.
Noteabsence of phase I (relaxation) in the ring without
endothelium. W0 = washout.
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nary artery disease induced transient inhibition of basal ten-
sion in quiescent coronary artery rings with endothelium; a
rapid relaxation (phase I) was followed by an increase in
tension toward the initial tension level (phase 2) (Fig. I and
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Figure 3. Correlation between number of large epicardial coro-
nary arteries with narrowing (as evidenced by coronary arteriog-
raphy) and relative vasoconstrictor activity (expressed as percent-
ageof contractile response induced by 20 mM of potassium chloride
IKCI]; 100% = 5.2 ± 1.2 g) of coronary sinus plasma sample
taken from the nine patients with severe(~50% narrowing)coro-
nary artery disease.
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2). No relaxation was observed in rings without endothe-
lium; arterial plasma induced only a moderate increase in
basal tension (Fig . I) . Platelet-rich plasma withdrawn from
the coronary sinus of patients with coronary artery disease
induced a smaller initial relaxation (phase I) followed by a
significantly (p < 0.05) greater increase in tension (phase
2) in bioassay rings with endothelium than that observed
with arteria l plasma samples (Fig. I and 2). In rings without
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Figure 2. Vasoactive properties of platelet-rich plasma samples
taken from various sites during rest and during mild (300 kp-rn)
or heavy(600or 900kp-m)supinebicycleexercise ineightpatients
with coronary artery disease. Open columns represent initial re-
laxation (phase I) and hatched columns show secondary increase
in tension (phase 2) (see Fig. I and inset) of bioassay canine
coronary artery rings with endothelium after addition of 1 ml
plasma samples into a 20 ml muscle bath. Data are shown as
means ± SE.
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dothelium, platelet-poor plasma samples caused vasocon-
striction (2.1 ± 0.3 g) comparable with that observed with
platelet-rich plasma samples (2.2 ± 0.4 g).
Patients with normal coronary arteries (Fig. 4). In
contrast to plasma samples taken from patients with coro-
nary artery disease, the arterial and coronary sinus platelet-
rich plasma samples from the five patients with angiograph-
ically normal coronary arteries induced only relaxation in
rings with endothelium and no change in basal tension of
rings without endothelium (data not shown). Mild or heavy
exercise did not modify the vasoactive properties of the
plasma (Fig. 4).
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Figure 4. Vasoactive properties of arterial and coronary sinus
platelet-rich plasma samples taken during rest and during mild
(300 kp-m) or heavy (600 or 900 kp-m) supine bicycle exercise
from four patients with normal coronary arteries. Open columns
represent initial relaxation (phase I) and hatched columns rep-
resent later steady state level of response (phase 2) (see Fig. I and
inset) observed in bioassay canine coronary artery rings with en-
dothelium after addition of I ml plasma samples into a 20 ml
muscle bath. Data are shown as means ± SE.
Pharmacologic Analysis of the Possible Identity of
the Vasoconstrictor Plasma Factor (Fig. 5)
Eight coronary artery rings (all withoutendothelium) were
studied in parallel. One served as control, and inhibitors of
known endogenous vasoactive substances were added to the
other rings 40 minutes before the addition of platelet-rich
plasma samples taken from the coronary sinus of patients
with coronary artery disease. After repeated washout (for
approximately 60 minutes) and readdition of the blocking
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Figure5. Effect of various pharmacologic inhibitors on isometric
tension response of bioassay rings without endothelium. Response
was induced by platelet-rich plasma samples (I :20dilution) taken
during rest from thecoronary sinus andsuperior vena cavaof five
patients with coronary artery disease. Data areexpressed aspercent
of contractile response to 20mM of potassium chloride (KCI) and
are shown as means ± SE of five (coronary sinus samples) and
three (venous samples) experiments, respectively. Asterisks =
statistically significant (p < 0.05)difference from control. NDGA
= nordihydroguaiaretic acid.
30
endothelium, the sample of coronary sinus plasma induced
pronounced vasoconstriction (Fig. I). The platelet-rich plasma
taken under identical conditions from the superior vena cava
of the same patient caused only relaxation in rings with
endothelium (Fig. I and 2) and no change in basal tension
of rings without endothelium (Fig. I).
The vasoactive properties of plasma samples taken dur-
ing exercise were not significantly different from those of
samples obtained during rest (Fig. 2). No significant dif-
ferences were found between vasoactive properties of plasma
taken from patients with coronary artery disease who did
(five patients) or did not (three patients) have chest pain and
ECG signs of myocardial ischemia during exercise.
The relative vasoconstrictor activity of coronary sinus
plasma (expressed as the percent of the contractile response
induced by 20 mM of potassium chloride; 100% = 5.6 ±
1.2 g) was significantly greater with samples taken from
patients with significant coronary artery disease (2::50% lu-
minal diameter narrowing) than with samples from patients
with mild coronary artery disease «50% narrowing). In
the patients with significant coronary artery disease, a sig-
nificant positive correlation was found between the number
of narrowed vessels and the vasoconstrictor activity of the
coronary sinus plasma (Fig. 3).
Coronary sinus plasma samples from three patients with
significant coronary artery disease were divided into two
portions: one analyzed as such (platelet-rich fraction) and
the other after centrifugation at 3,000 rpm for 30 minutes
to gain platelet-poor plasma. In bioassay rings without en-
JACC Vol. 9, No.6
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drugs, the effects of plasma samples from the superior vena
cava of the same patients were tested as well,
The results offive similar experiments are demonstrated
in Figure 5, The significant vasoconstriction induced by
coronary sinus plasma samples and the lack of effect (that
is, no significant difference from initial basal tension; see
Figure I) of systemic venous plasma samples were not af-
fected by the lipoxygenase inhibitor nordihydroguaiaretic
acid (10- 5 M), by histaminergic (mepyrarnine, 10- 5 M)
and adrenergic (propranolol, 5 x 10- 6 M; phentolamine,
5 x 10- 6 M) receptor antagonists, or by the adenosine
triphosphatase and diphosphatase apyrase (0,8 U/ml). The
cyclooxygenase inhibitor indomethacin (10- 5 M) increased
basal tension (by 1.5 ± 0.2 g; p < 0,05) and significantly
augmented the vasoconstrictor response of the coronary si-
nus plasmasamples. In contrast to control conditions, plasma
samples from the superior vena cava produced significant
increase in tension above basal level in the presence of
indomethacin, The nonselective serotoninergic receptor
blocker rnethiothepin (2 x 10- 6 M) prevented the vaso-
constriction induced by the coronary sinus plasma sample
without affecting the initial basal tension or the contractile
response to potassium chloride (data not shown).
Discussion
Vasoconstrictor activity in the coronary sinus plasma
from patients with organic coronary artery stenosis. We
have documented significant vasoconstrictor activity of
platelet-rich and platelet-poor plasma samples taken from
the coronary sinus of patients with coronary artery disease,
The absence of such vasoconstrictor activity in the coronary
sinus plasma of patients with angiographically normal coro-
nary arteries suggests a close relation between the vasocon-
strictor activity and the existence of coronary artery disease.
Although blood samples were taken from patients with and
without coronary artery disease under identical conditions,
the possibility that the vasoconstrictor activity is the result
of blood withdrawal cannot be excluded (see also later).
That the vasoconstrictor activity is the consequence of the
passage of blood through the heart is evidenced by the
absence of a significant vasoconstrictor activity of plasma
samples taken from a systemic artery or from the superior
vena cava of the same patients with coronary artery disease.
It is also obvious that the appearance of the factor or factors
is not triggered by acute myocardial ischemia, because I)
the activity could be detected in patients under rest condi-
tions with no apparent sign of myocardial ischemia and 2)
during exercise there was no difference in vasoconstrictor
activity between patients in whom chest pain and ECG signs
of ischemia developed and those in whom they did not.
The coronary sinus plasma samples from patients with
coronary artery disease evokedvasoconstriction of thebioassay
canine coronary artery rings with intact endothelium after
an initial transient relaxation. Because all of the plasma
samples tested induced initially an endothelium-dependent
relaxation, it seems to be a common property of human
plasma. The factor or factors responsible for such relaxation
are not known at present, but the effect can be attributed
to various substances (for example, thrombin, adenosine
triphosphateand diphosphate) known to be present in plasma
and able to induce endothelium-dependent relaxation of iso-
lated blood vessels (11,12).
Possible nature of the factor or factors responsible
for the vasoconstrictor activity: role of serotonin. As a
first attempt to characterize the nature of the vasoconstrictor
plasma factor or factors, we used inhibitors of some of the
known vasoactive substances that may be present in plasma
to test how they affect the vasoconstrictoractivity. We found
that among the inhibitors used, only the nonselective se-
rotoninergic antagonist methiothepin prevented the vaso-
constriction. At a concentration used in the present study,
methiothepin inhibits the vasoconstriction of canine coro-
nary artery rings induced by 5-hydroxytryptamine (9) but
not by potassium chloride (present observation) or hypoxia
(8), Although methiothepin may inhibit alpha-adrenergic
receptors (13), it cannot be responsible for the prevention
of the vasoconstrictioninducedby the coronary sinus plasma
samples, because the nonselective alpha-adrenergic receptor
blocker phentolamine was ineffective. Thus, it can be as-
sumed that 5-hydroxytryptamine(serotonin) may be, at least
in part, responsible for the vasoconstrictor activity of the
coronary sinus plasma samples. Serotonin evokes vasocon-
striction in coronary artery vascular smooth muscle (9,14,15)
and is released from aggregating platelets (16). We therefore
postulate that platelets are activated during their passage
over the atheromatous plaques of coronary arteries and that
they release the potent vasoconstrictor serotonin, which can
be detected by bioassay in the blood leaving the heart.
Indeed. earlier studies demonstrated reduced platelet sur-
vival (17,18), increased platelet adhesiveness and aggreg-
ability in vitro (19,20), and increased circulating platelet
aggregates in coronary sinus blood (21) taken from patients
with various clinical manifestations of ischemic heart dis-
ease. Elevated coronary sinus plasma levels of platelet-spe-
cific proteins (like platelet factor 4 and beta-thromboglob-
ulin) in patients with chronic stable atheromatous coronary
artery disease (22-26) support the postulation that the ob-
served vasoconstrictor activity may be the result of platelet
activation during passage of the platelets over atheromatous
plaques. This hypothesis may be supported further by the
present finding that the more severe the coronary artery
stenosis or the more the vessels were narrowed, the greater
the vasoconstrictor activity of the coronary sinus plasma
samples.
That the vasoconstrictor activity is not a consequence of
platelet aggregation in Krebs solution or on the surface of
the bioassay vascular rings is evidenced by the findings that
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platelet-poor plasma samples exhibit vasoconstrictor activity
similar to that of the platelet-rich plasma samples. Thus,
the vasoconstrictor factor (possibly 5-hydroxytryptamine)
has already been released into the plasma before its addition
to the organ chamber. However, the possibility cannot be
excluded that because of their increased aggregability (19,20),
the partially activated platelets in the coronary sinus blood
aggregated further during the preparation procedure (col-
lection, centrifugation and so forth).
Pathogenetic consequences and therapeutic consid-
eration. According to these earlier and present findings,
activation of a pathologic vasoconstrictor mechanism (that
is, release of a vasoconstrictor factor from platelets) at the
site of atheromatous plaques may contribute to or be re-
sponsible for the frequent occurrence of vasospastic epi-
sodes in the vicinity of such lesions. In addition, damage
of the normal function of the endothelium can also contribute
to the development of such spasm not only by promoting
platelet activation but also by making the underlying vas-
cular smooth muscle cells "hypersensitive" to vasocon-
strictor stimuli (9, 11,12,14,15).
This speculation leads to a reconsideration of the use of
antiplatelet aggregation drugs in patients with atheromatous
coronary artery disease to prevent such vasospastic epi-
sodes. Clinical trials using antiplatelet drugs in coronary
artery disease have not shown consistently beneficial effects
(27,28), although a recent trial using aspirin in patients with
unstable angina demonstrated a striking reduction in mor-
tality and subsequent myocardial infarction (29). A potential
disadvantage of cyclooxygenase inhibitors, such as aspirin,
is related to inhibition of the production of prostacyclin (the
natural antiplatelet substance) by endothelial cells. In ad-
dition, the present findings indicate that indomethacin (an-
other cyclooxygenase inhibitor) can make coronary arterial
vascular smooth muscle cells "hypersensitive" to normally
occurring vasoconstrictor stimuli, as evidenced by the pro-
nounced vasoconstrictionproduced by systemicvenous plasma
samples only in the presence of the drug.
It is suggested that the use of other antiplatelet drugs
(which act by mechanisms other than inhibition of cycloox-
ygenase) may be therapeutically beneficial. Recent reports
demonstrated that ticlopidine (a drug that enhances the anti-
aggregative effects of endogenous prostacyclin and also has
direct antiaggregative action [30]) effectively prevents plate-
let activation (22) and decreases the number of ischemic
episodes in patients with stable coronary artery disease (31).
Contribution to myocardial ischemia. The presence of
a vasoconstrictor factor in the coronary sinus blood of pa-
tients with coronary artery disease but without apparent
myocardial ischemia at the time of sampling provokes spec-
ulations on the potential contribution of this factor (or fac-
tors) to silent myocardial ischemia (32,33). Continuing ac-
tivation of platelets at the site of damaged coronary artery
endothelium may result in the release of vasoactive sub-
stances without provoking ischemia until additional stimuli
occur. The vasoconstrictor factor or factors in combination
with damaged endothelial function in the vicinity of ather-
omatous lesion (34) may increase the sensitivity of vascular
smooth muscle cells to other stimuli, and when acting si-
multaneously, they may provoke flow-limiting stenosis and
myocardial ischemia.
Our study demonstrates for the first time in a bioassay
system an apparent release of serotonin into coronary sinus
blood of patients with coronary artery disease. A role for
serotonin in providing coronary vasospasm has already been
suggested in an experimental model of coronary artery dis-
ease (35). Exercise did not provoke a statistically significant
increase in the peak vasoconstrictor activity, but there was
a decrease in the initial relaxation phase and a trend toward
increased vasoconstrictor activity. This blunting in the initial
relaxation phase may be related to an impaired release of
vasodilator factor or factors during exercise, dilutional ef-
fects of an increase in coronary blood flow or other mech-
anisms not clear at present. An imbalance favoring vaso-
constriction may then result in myocardial ischemia, perhaps
silent (32,33) or clinically evident, depending on the se-
verity of the disturbed relation.
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